A Phase II Study of Nimotuzumab in Patients with Unresectable Stage III Non-small Cell Lung Cancer

Trial Profile

A Phase II Study of Nimotuzumab in Patients with Unresectable Stage III Non-small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2016

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 23 Sep 2011 Interim results to be reported at a scientific conference in the third quarter of 2011, according to a YM BioSciences media release
    • 10 Feb 2011 Daiichi Sankyo advised YM BioSciences that recruitment completed and data expected in the first half of 2011, according to a YM BioSciences media release
    • 11 Nov 2010 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top